SHYNDEC(SH:600420) Di Yi Cai Jing·2025-12-25 08:54Core Viewpoint - The announcement by China National Pharmaceutical Group Modern indicates that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Fumaric Acid Quetiapine Extended-Release Tablets, a novel atypical antipsychotic medication [1] Group 1 - Fumaric Acid Quetiapine Extended-Release Tablets are primarily used for the treatment of schizophrenia and bipolar disorder, helping to stabilize mood, reduce hallucinations, and improve cognitive function [1] - The total research and development investment for Fumaric Acid Quetiapine Extended-Release Tablets (300mg) by China National Pharmaceutical Group Industrial has reached approximately RMB 10.407 million (unaudited) [1]